医学
恶心
化疗引起恶心呕吐
呕吐
头颈部癌
止吐药
化疗
队列
内科学
癌症
麻醉
肿瘤科
作者
Jordan A. Stinson,Kelvin Chan,Justin Lee,Ronald Chow,Paul Cheon,Angie Giotis,Mark Pasetka,Bo Wan,Edward Chow,Carlo DeAngelis
出处
期刊:Annals of palliative medicine
[AME Publishing Company]
日期:2017-08-01
卷期号:6 (S1): S13-S20
被引量:4
标识
DOI:10.21037/apm.2017.03.05
摘要
Background: The purpose was to retrospectively examine the anti-emetic regimens prescribed for prophylaxis of chemotherapy-induced nausea and vomiting (CINV) for head and neck cancer patients receiving moderate- or high-emetogenic chemotherapy (MEC/HEC) along with concurrent radiation treatment at an outpatient ambulatory care center to determine the efficacy of anti-emetics prescribed. Methods: Consecutive patients with head and neck cancers who initiated cisplatin chemotherapy with concurrent radiation treatment between January 2013 and June 2015 were investigated. Patients’ anti-emetic use and occurrence of CINV was extracted from available clinical documentation. Patients were divided into two cohorts: CISPL-HIGH (n=161), and CISPL-WEEKLY (n=38). Results: A total of 199 head and neck cancer patients (158 male, 41 female) were included in the analysis (mean age =59 years). In the CISPL-HIGH cohort, 33 males (26%) and 16 females (49%) experienced CINV. In the CISPL-WEEKLY cohort, four males (13%) and two females (25%) experienced CINV. Nausea occurred in 71 patients (62 HEC and 9 MEC). The odds of achieving complete response (no nausea or vomiting) were 3.5 (P Conclusions: In the current study CINV control for patients receiving HEC was sub-optimal. Changes to our prophylactic antiemetic regimens may help improve patient outcomes.
科研通智能强力驱动
Strongly Powered by AbleSci AI